Monomerization of C-reactive protein requires glycoprotein IIb-IIIa activation: Pentraxins and platelet deposition

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 11, 2013, Pages 2048-2058

  de la Torre, R ^a   Pena E ^a   Vilahur, G ^a   Slevin, M ^a,b   Badimon, L ^a,b,c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

C reactive protein; Hydroxymethylglutaryl CoA reductase inhibitors; Platelets; Serum amyloid P component; Thrombosis

Indexed keywords

AMINOPHOSPHOLIPID; C REACTIVE PROTEIN; COLLAGEN; COLLAGEN FIBRIL; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRONECTIN; LIPOCORTIN 5; PENTRAXIN; SCLEROPROTEIN; SERUM AMYLOID P; SIMVASTATIN; ISOPROTEIN; NERVE PROTEIN; PHOSPHOLIPID;

ARTICLE; BLOOD CLOTTING; BOUNDARY LAYER; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; NORMAL HUMAN; POLYMERIZATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SHEAR RATE; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOGENICITY; THROMBOSIS; CELL ADHESION; INFLAMMATION; INNATE IMMUNITY; METABOLISM; SHEAR STRENGTH;

ANNEXIN A5; BLOOD PLATELETS; C-REACTIVE PROTEIN; CELL ADHESION; HEALTHY VOLUNTEERS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NERVE TISSUE PROTEINS; PHOSPHOLIPIDS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN ISOFORMS; SERUM AMYLOID P-COMPONENT; SHEAR STRENGTH; SIMVASTATIN; THROMBOSIS;

EID: 84887539928     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12415     Document Type: Article

References (38)

1. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005; 166: 1265-71.
2. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. 2006; 113: 2135-50; discussion 50.
3. Singh SK, Suresh MV, Voleti B, Agrawal A. The connection between C-reactive protein and atherosclerosis. Ann Med 2008; 40: 110-20.
4. Blake GJ, Ridker PM. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003; 41: 37S-42S.
5. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
6. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
7. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-90.
8. Jabs WJ, Theissing E, Nitschke M, Bechtel JF, Duchrow M, Mohamed S, Jahrbeck B, Sievers HH, Steinhoff J, Bartels C. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003; 108: 1428-31.
9. Shrive AK, Cheetham GM, Holden D, Myles DA, Turnell WG, Volanakis JE, Pepys MB, Bloomer AC, Greenhough TJ. Three dimensional structure of human C-reactive protein. Nat Struct Biol 1996; 3: 346-54.
10. Diehl EE, Haines GK 3rd, Radosevich JA, Potempa LA. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 2000; 319: 79-83.
11. Krupinski J, Turu MM, Martinez-Gonzalez J, Carvajal A, Juan-Babot JO, Iborra E, Slevin M, Rubio F, Badimon L. Endogenous expression of C-reactive protein is increased in active (ulcerated noncomplicated) human carotid artery plaques. Stroke 2006; 37: 1200-4.
12. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res 2009; 105: 128-37.
13. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, Zhao J. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J 2007; 21: 284-94.
14. Khreiss T, Jozsef L, Potempa LA, Filep JG. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 2004; 109: 2016-22.
15. Khreiss T, Jozsef L, Potempa LA, Filep JG. Opposing effects of C-reactive protein isoforms on shear-induced neutrophil-platelet adhesion and neutrophil aggregation in whole blood. Circulation 2004; 110: 2713-20.
16. Molins B, Pena E, Vilahur G, Mendieta C, Slevin M, Badimon L. C-reactive protein isoforms differ in their effects on thrombus growth. Arterioscler Thromb Vasc Biol 2008; 28: 2239-46.
17. Badimon L, Chesebro JH, Badimon JJ. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 1992; 86: III74-85.
18. Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res 2001; 104: 149-74.
19. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009; 103: 4A-10A.
20. Ruggeri ZM, Orje JN, Habermann R, Federici AB, Reininger AJ. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903-10.
21. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
22. Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol 1998; 30: 1415-26.
23. Molins B, Pena E, de la Torre R, Badimon L. Monomeric C-reactive protein is prothrombotic and dissociates from circulating pentameric C-reactive protein on adhered activated platelets under flow. Cardiovasc Res 2011; 92: 328-37.
24. Pepys MB, Gallimore JR, Lloyd J, Li Z, Graham D, Taylor GW, Ellmerich S, Mangione PP, Tennent GA, Hutchinson WL, Millar DJ, Bennett G, More J, Evans D, Mistry Y, Poole S, Hawkins PN. Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use. J Immunol Methods 2012; 384: 92-102.
25. Hutchinson WL, Hohenester E, Pepys MB. Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol Med 2000; 6: 482-93.
26. Li XA, Hatanaka K, Ishibashi-Ueda H, Yutani C, Yamamoto A. Characterization of serum amyloid P component from human aortic atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1995; 15: 252-7.
27. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Serum amyloid P and cardiovascular disease in older men and women: results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 2007; 27: 352-8.
28. Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. J Lab Clin Med 1987; 110: 706-18.
29. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
30. Turitto VT, Baumgartner HR. Platelet deposition on subendothelium exposed to flowing blood: mathematical analysis of physical parameters. Trans Am Soc Artif Intern Organs 1975; 21: 593-601.
31. Habersberger J, Strang F, Scheichl A, Htun N, Bassler N, Merivirta RM, Diehl P, Krippner G, Meikle P, Eisenhardt SU, Meredith I, Peter K. Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res 2012; 96: 64-72.
32. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-12.
33. Baltz ML, Caspi D, Evans DJ, Rowe IF, Hind CR, Pepys MB. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986; 66: 691-700.
34. Talens S, Leebeek FW, Demmers JA, Rijken DC. Identification of fibrin clot-bound plasma proteins. PLoS One 2012; 7: e41966.
35. Vilahur G, Segales E, Salas E, Badimon L. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model. Circulation 2004; 110: 1686-93.
36. Zafar MU, Vilahur G, Choi BG, Ibanez B, Viles-Gonzalez JF, Salas E, Badimon JJ. A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost 2007; 5: 1195-2000.
37. Lee YM, Chen WF, Chou DS, Jayakumar T, Hou SY, Lee JJ, Hsiao G, Sheu JR. Cyclic nucleotides and mitogen-activated protein kinases: regulation of simvastatin in platelet activation. J Biomed Sci 2010; 17: 45.
38. Molins B, Pena E, Padro T, Casani L, Mendieta C, Badimon L. Glucose-regulated protein 78 and platelet deposition: effect of rosuvastatin. Arterioscler Thromb Vasc Biol 2010; 30: 1246-52.